Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation
|
|
- Ross McKinney
- 5 years ago
- Views:
Transcription
1 Received: 3 November 2016 Revised: 16 November 2016 Accepted: 21 November 2016 DOI /ajh RESEARCH ARTICLE Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation Hideki Nakasone 1 Fuji Shigeo 2 Kimikazu Yakushijin 3 Makoto Onizuka 4 Akihito Shinohara 5 Kazuteru Ohashi 6 Koichi Miyamura 7 Naoyuki Uchida 8 Minoko Takanashi 9 Tatsuo Ichinohe 10 Yoshiko Atsuta 11,12 Takahiro Fukuda 2 Masao Ogata, 13 On Behalf of the Complication Working Group of Japanese Society for Hematopoietic Cell Transplantation 1 Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan; 2 Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; 3 Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan; 4 Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan; 5 Department of Hematology, Tokyo Women s Medical University, Tokyo, Japan; 6 Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; 7 Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; 8 Department of Hematology, Toranomon Hospital, Tokyo, Japan; 9 Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan; 10 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; 11 Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; 12 Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan; 13 Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan Correspondence Hideki Nakasone MD/PhD, Division of Hematology, Saitama Medical Center, Jichi Medical University, Amanuma-cho Omiya-ku, Saitama, , Japan. nakasone-tky@umin.ac.jp Funding Information This work was supported in part by a Research Grant for Allergic Disease and Immunology from the Japanese Ministry of Health, Labor, and Welfare (Y.A.). H.N. was a recipient of research awards from Jichi Medical University. Abstract Total body irradiation (TBI) has been thought to promote donor cell engraftment in allogeneic hematopoietic cell transplantation (HCT) from alternative donors. However, recent progress in HCT strategies may affect the clinical significance of TBI on neutrophil engraftment. With the use of a Japanese transplant registry database, we analyzed 3933 adult recipients (>15 y.o.) who underwent HCT between 2006 and 2013 from an 8/8 HLA-matched unrelated bone marrow donor (MUD, n ), an HLA-mismatched unrelated bone marrow donor (MMUD, n ), or unrelated cord blood (CBT, n ). Conditioning regimens were divided into five groups: High-TBI-(>8Gy), Low-TBI- (8Gy), and no-tbi-myeloablative conditioning (MAC), and Low-TBIand no-tbi-reduced-intensity conditioning (RIC). In both MUD and MMUD, neutrophil engraftment rate was >90% in each of the five conditioning groups, and TBI was not associated with prompt neutrophil engraftment in multivariate analyses. Conversely, in CBT, TBI regimens had a higher rate of day-30 neutrophil engraftment than no-tbi-regimens: 78% in High-TBI-MAC, 83% in Low-TBI-MAC, and 76% in Low-TBI-RIC versus 65% in No-TBI-MAC, and 68% in No-TBI-RIC (P <.001). Multivariate analyses in CBT demonstrated that TBI-regimens were significantly associated with a higher rate of neutrophil engraftment. Subsequently focusing on CBT patients alone, TBI-regimens were significantly associated with a higher rate of neutrophil engraftment in patients who received CBT with a 4/6 or less HLA allele-match, or who had anti-hla antibodies. In summary, TBI-regimens had no impact on neutrophil engraftment in the current practice of unrelated bone marrow transplantation. However, in CBT, TBI is still necessary to enhance engraftment. Conflicts of Interest: The authors report no potential competing conflicts of interest. Am J Hematol 2017; 92: wileyonlinelibrary.com/journal/ajh VC 2016 Wiley Periodicals, Inc. 171
2 172 1 INTRODUCTION Allogeneic hematopoietic cell transplantation (HCT) has been developed as a curative treatment for hematological malignancies. HCT recipients will frequently experience various adverse events, and all of them initially have to achieve donor cell engraftment during the first month following HCT to acquire an allogeneic anti-leukemia/lymphoma effect. Historically, allogeneic HCT has spread widely since the initial success of high-dose total body irradiation (TBI) with cyclophosphamide (CY) 50-year ago. Since then, TBI with CY has been the standard myeloablative conditioning (MAC) regimen. 1 Conversely, a higher dose of irradiation has been shown to result in increased organ toxicities, 2 5 although it was also linked to a reduced risk of leukemia relapse. 1,6 Therefore, to reduce the adverse toxicities due to TBI, clinical investigators have explored alternative strategies including no-tbi or reduced-intensity conditioning (RIC). However, these strategies might raise a concern of graft failure in an unrelated transplant or HLAmismatched transplant setting due to insufficient immunosuppression, as reported in early studies. 1,7 10 Therefore, TBI has been widely incorporated into conditioning regimens because of its theoretical potential to suppress recipient-side immunity and prevent graft rejection, in addition to enhanced anti-leukemic effects. However, recent progress with conditioning strategies, donor source selection algorithms, graftversus-host disease (GVHD) prophylaxis, and various approaches to supportive care may improve sustained engraftment even in these alternative HCT settings. To the best of our knowledge, there have been no reports in large cohorts that comprehensively assessed the impact of TBI on neutrophil engraftment in the setting of unrelated HCT as a primary endpoint. Thus, the impact of TBI on neutrophil engraftment following HCT from an unrelated bone marrow (BMT) or cord blood donor was retrospectively analyzed using a Japanese transplant registry database. First, the impact of TBI on cumulative neutrophil engraftment was analyzed in each donor cohort. Next, we evaluated the effects of TBI in subgroups of the unrelated cord blood transplantation (CBT) stratified according to conditioning intensity, number of HLA-matches, and the presence of anti-hla antibodies. 2 PATIENTS AND METHODS 2.1 Definitions of categories Neutrophil engraftment was defined as the first of three sequential days when the neutrophil count was > /L. Conditioning regimens that included TBI > 8 Gy, melphalan (Mel) > 140 mg/m 2, or oral busulfan (Bu) 9 mg/kg (i.v. Bu 72 mg/kg) were classified as MAC. Other regimens were classified as RIC Conditioning regimens were then divided into five groups: High-TBI (> 8Gy)-MAC, Low-TBI ( 8Gy)-MAC, no-tbi-mac, Low-TBI-RIC, and no-tbi-ric. HLAmatch was defined as an 8/8 allelic match of HLA-A, -B, -C, and -DRB1 in unrelated BMT, or a 6/6 allelic match of HLA-A, -B, and -DRB1 in CBT. 2.2 Patient selection We retrospectively analyzed 3933 adult and adolescent recipients (>15- year old) who underwent their 1st HCT from an unrelated donor between 2006 and 2013: 8/8 HLA-matched unrelated bone marrow donor (MUD, n ), HLA-mismatched unrelated bone marrow donor (MMUD, n ), and unrelated cord blood (CBT, n ). HCT with unrelated peripheral blood stem cells was excluded, since it was rarely available in Japan during the evaluation period. Additionally, only standard-risk leukemia patients were included: 1st or 2nd complete remission of acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), 1st or 2nd chronic phase of chronic myeloid leukemia, and myelodysplastic syndrome (MDS) other than refractory anemia with excess blasts. The data were reported to the Japan Society for Hematopoietic Cell Transplantation through the Transplant Registry Unified Management Program in For recipients to be considered eligible, information on age, sex, HLA, conditioning regimen, neutrophil engraftment, and survival status at the end of follow-up were required. High-TBI-MAC included TBI and CY-based regimens, while regimens that contained TBI with cytarabine alone or etoposide alone were excluded. Low-TBI-MAC included fludarabine(flu)-based Bu or Mel regimens with TBI. No-TBI-MAC included Bu with CY, and Flu-based Bu or Mel. RIC included only Flu-based regimens. Patients who received GVHD prophylaxis other than cyclosporine or tacrolimus-based strategies were excluded. This retrospective analysis was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board at Saitama Medical Center, Jichi Medical University. 2.3 Statistical analysis Categorical variables were compared using the chi-square test. The probabilities of cumulative neutrophil engraftment in each conditioning type were estimated and separately compared by Gray s methodin individual donor cohorts, where death before engraftment was considered as a competing risk. These probabilities were estimated with a 95% confidence interval (CI). The Cox proportional hazard model was used in a multivariate analysis. In the multivariate analysis, the hazard ratios (HR) of conditioning types were obtained after being adjusted for the following variables: gender, age, disease, performance status, GVHD prophylaxis, in vivo T-cell depletion, infused total nucleated cells (TNC), and use of granulocyte-colony stimulating factor (G-CSF). Statistical significance was defined as a two-tailed P-value of less than.05. All data management and statistical calculations were performed using Stata version 120 (Stata Corp., College Station, TX) and EZR, which is a graphical user interface for R (The R Foundation for Statistical Computing, version 322, Vienna, Austria) (Jichi Medical University at RESULTS 3.1 Patient characteristics Among the 3933 patients, the donor was MUD in 1367, MMUD in 1102, and CBT in 1464 (Table 1). The patient s medianagewas47
3 173 TABLE 1 Patient characteristics Total (n ) (%) MUD (n ) (%) MMUD (n ) (%) CBT (n ) (%) Age % % % % % % % % % % % % Gender Female % % % % Male % % % % Disease AML % % % % ALL % % % % MDS % % % 138 9% CML 143 4% 44 3% 42 4% 57 4% Performance Status PS % % % % PS % 43 3% 43 4% 75 5% Missing 15 0% CMV serostatus (D/R) Pos/Pos % % % 0 0% Pos/Neg 254 6% % % 0 0% Neg/Pos % % % % Neg/Neg % 118 9% 94 9% % Missing 280 7% Sex mismatch Matched % % % % Male to Female % % % % Female to Male % % % % Missing % Conditioning HighTBI_MAC % % % % LowTBI_MAC 222 6% 63 5% 59 5% 100 7% NoTBI_MAC % % % 77 5% LowTBI_RIC % % % % NoTBI_RIC 278 7% 112 8% 88 8% 78 5% GVHD prophylaxis CsA-based % % % % Tac-based % % % % T-cell depletion Without % % % % With 172 4% 25 2% 103 9% 44 3% Infused TNC [310 8/ kg (310 7/ kg in CBT)] < % % % % % % % % % % % 88 6% G-CSF Without 232 6% 113 8% 77 7% 42 3% With % % % % MUD, bone marrow transplant from an HLA-matched unrelated donor; MMUD, bone marrow transplant from an HLA-mismatched unrelated donor; CBT, unrelated cord blood transplant; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; PS, performance status; CMV, cytomegalovirus; Pos, positive; Neg, negative; TBI, total body irradiation; MAC, myeloablative conditioning; RIC, reducedintensity conditioning; GVHD, graft-versus-host disease; CsA, cyclosporine; Tac, tacrolimus; TNC, total nucleated cells; G-CSF, granulocyte-colony stimulating factor. (IQR:23), 46 (IQR:21), and 49 (IQR:24) years in the MUD, MMUD, and CBT cohorts, respectively. Half of the patients received High-TBI- MAC, and TBI-regimens were used in 80% of them. Tacrolimus-based GVHD prophylaxis was frequently used in MUD- and MMUD-BMT, while cyclosporine-based prophylaxis was frequently used in CBT. Most CBT patients (n , >98%) received single cord blood. The
4 174 FIGURE 1 (A) Neutrophil engraftment according to the conditioning type in the three donor cohorts. (B) Impact of TBI on neutrophil engraftment in the groups stratified according to the donor source and conditioning intensity in multivariate analyses of myeloablative and reduced-intensity conditioning cohorts. MUD, bone marrow transplant from an HLA-matched unrelated bone marrow donor; MMUD, bone marrow transplant from an HLA-mismatched unrelated bone marrow donor; CBT, unrelated cord blood donor transplant; TBI, total body irradiation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning. HR is shown, after being adjusted for gender, age, disease, performance status, GVHD prophylaxis, in vivo T-cell depletion, infused total nuclear cells, and use of granulocyte-colony stimulating factor median dose of infused TNC was 267 (IQR:127) /kg in the MUD group, 264 (IQR:121) /kg in the MMUD group, and 254 (IQR:085) /kg in the CBT group. G-CSF was used in >90% recipients for all types of donors. The details of the patient distributions among the conditioning types are shown in Supporting Information Tables S1 and S2, according to the individual donor cohorts (MUD, MMUD, and CBT) and conditioning intensity (MAC and RIC). In the MAC group, High-TBI regimens were frequently used for younger recipients (<50 y.o.) and those with ALL in any donor cohort (Supporting Information Table S1). There was no difference in infused cell doses among the conditioning types (Novs. Low- vs. High-TBI-MAC) in any donor cohort. In the RIC group, there was no difference in age, infused cell dose or G-CSF usage between conditioning types in any donor cohort (Supporting Information Table S2). 3.2 Neutrophil engraftment in the overall MUD, MMUD, and CBT cohorts Overall neutrophil engraftment at 30 days post-hct was 96% (95%CI: 95%-97%), 95% (95%CI: 94%-96%), and 77% (95%CI: 74%-79%) in the MUD, MMUD, and CBT cohorts, respectively. In the MUD cohort, there was no difference in engraftment achievement among the types of conditioning in a univariate analysis (P 5.34, Figure 1A), and more than 95% of recipients could achieve neutrophil engraftment by 30 days post-hct in all types of conditioning [96% (95%CI: 94%-97%) in High-TBI-MAC, 97% (95%CI: 85%- 99%) in Low-TBI-MAC, 97% (95%CI: 94%-99%) in No-TBI-MAC, 97% (95%CI: 93%-98%) in Low-TBI-RIC, and 96% (95%CI:89%-98%) in No- TBI-RIC]. The median time to neutrophil engraftment were 17 days in High-TBI-MAC and Low-TBI-RIC, and 16 days in Low-TBI-MAC,
5 175 FIGURE 2 Cumulative neutrophil engraftment in the unrelated cord blood transplant (CBT) sub-cohorts with (A) a 6/6 or 5/6 HLA allele match and MAC (n 5 101), (B) a 4/6 or less HLA allele match and MAC (n 5 788), (C) a 6/6 or 5/6 HLA allele match and RIC (n 5 79), and (D) a 4/6 or less HLA allele match and RIC (n 5 420). (E) Multivariate analyses for the impact of TBI on neutrophil engraftment in the CBT sub-cohorts. HR is shown, after being adjusted for gender, age, disease, performance status, GVHD prophylaxis, in vivo T-cell depletion, infused total nuclear cells, and use of granulocyte-colony stimulating factor. TBI, total body irradiation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning No-TBI-MAC, and -RIC. In multivariate analyses, TBI-regimens were not associated with prompt neutrophil engraftment (Supporting Information Table S3). Rather, High-TBI-MAC was associated with delayed engraftment [HR 085 (95%CI: ), P 5.048]. In the MMUD cohort, neutrophil engraftment was sufficiently achieved in all of the five conditioning types, although patients with TBI-MACs had higher probabilities of neutrophil engraftment at 30 days post-hct: 97% (95%CI: 95%-98%) in High-TBI-MAC, 97% (95%CI: 85%-99%) in Low-TBI-MAC, 95% (95%CI: 91%-97%) in No- TBI-MAC, 92% (95%CI: 87%-95%) in Low-TBI-RIC, and 93% (95%CI: 85%-97%) in No-TBI-RIC (P 5.02, Figure 1A). The median time to neutrophil engraftment were 17 days in High-TBI-MAC and Low-TBI-RIC, and 16 days in Low-TBI-MAC, No-TBI-MAC, and -RIC. However, in a multivariate analysis, there was no difference in neutrophil engraftment among the five conditioning types (Supporting Information Table S3). Conversely, in the CBT cohort, the probabilities of neutrophil engraftment at 30 days post-hct were significantly higher in TBI-regimens: 78% (95%CI: 75%-81%) in High-TBI-MAC, 83% (95%CI: 74%- 89%) in Low-TBI-MAC, and 76% (95%CI: 72%-80%) in Low-TBI-RIC versus 65% (95%CI: 53%-75%) in No-TBI-MAC, and 68% (95%CI: 56%-77%) in No-TBI-RIC (P <.001, Figure 1A). The median time to neutrophil engraftment were 23 days in High-TBI-MAC, 19 days in Low-TBI-MAC, 22 days in No-TBI-MAC, 21 days in Low-TBI-RIC, and 24 days in No-TBI-RIC. Multivariate analyses also demonstrated that TBI-regimens were significantly associated with a higher rate of neutrophil engraftment (Supporting Information Table S3). When we separately analyzed the impact of TBI in the MAC and RIC sub-cohorts, TBI had a favorable impact on neutrophil engraftment in the CBT cohort, but not in the MUD or MMUD cohort (Figure 1B). In summary, TBI did not have a favorable impact on successful neutrophil engraftment in unrelated BMT. Conversely, in the CBT cohort, TBI had a significantly favorable effect on neutrophil engraftment in both the MAC and RIC groups. Therefore, in subsequent analyses, we explored the significance of incorporating TBI into conditioning regimens, with a particular focus on the CBT sub-cohorts stratified according to HLA match, infused cell dose, and the presence of anti- HLA antibody. 3.3 Subgroup analyses according to HLA allelematch and conditioning intensity in the CBT cohort In the CBT sub-cohorts with a 6/6 or 5/6 HLA allele-match between the donor and recipient, there was no difference in neutrophil engraftment among the conditioning types in the MAC or RIC groups (Figure 2A,C). Conversely, in the CBT sub-cohort with a 4/6 or less HLA allelematch, recipients with TBI-regimens had a higher rate of neutrophil engraftment (Figure 2B,D), and TBI was significantly associated with neutrophil engraftment in both the MAC and RIC groups (Figure 2E). If we focused on the number of HLA-match of host-versus-graft (HVG) direction in the CBT group, the favorable effect of TBI on neutrophil engraftment was also observed in the subgroup with 4 or less HLA match of HVG direction, but not observed in the CBT subgroup with
6 176 Low-TBI: 22 (95%CI: 12-43), P 5.02]. In summary, the use of TBI might enhance neutrophil engraftment even in recipients with anti- HLA antibodies. 3.6 Impact of TBI on other outcomes in HCT from MUD, MMUD, and CBT Although the primary endpoint of this study was neutrophil engraftment, the impact of TBI on other outcomes was also assessed (Supporting Information Figure S3). In the CBT cohort, TBI-regimens tended to be associated with a lower risk of non-relapse mortality. 4 DISCUSSION FIGURE 3 Cumulative neutrophil engraftment according to TBI intensity in CBT recipients with anti-hla antibodies (n 5 173) HLA-match or one mismatch of HVG direction. In summary, TBIregimens appear to have a favorable effect on neutrophil engraftment when used along with CBT with a 4/6 or less HLA allele-match. 3.4 Subgroup analyses in CBT recipients with lower TNC or CD34-positive cell doses Next, we analyzed the impact of TBI in recipients with lower infused TNC and/or CD34-positive cell doses, which are generally considered to be risk factors for graft rejection in CBT. 16 Among recipients with a lower TNC dose (< /kg), those with TBI-regimens tended to have higher rates of neutrophil engraftment (Supporting Information Figure S1-A & S1-B). However, multivariate analyses suggested that TBI-regimens, except for Low-TBI-MAC, were not associated with prompt engraftment (Supporting Information Figure S1-C). Among recipients with lower CD34-positive cell doses (< /kg), those with TBI-regimens tended to have higher rates of neutrophil engraftment (Supporting Information Figure S2-A & S2-B). Multivariate analyses revealed that TBI-regimens were significantly associated with higher rates of neutrophil engraftment in the MAC group, but not in the RIC group (Supporting Information Figure S2-C). In summary, when CBT with low doses of infused TNC or CD34- positive cells was selected, TBI seemed to have a favorable effect on neutrophil engraftment only in specific MAC regimens. 3.5 Subgroup analyses in CBT recipients with anti-hla antibodies Furthermore, we analyzed the impact of TBI in recipients who had detectable anti-hla antibodies prior to HCT, which is also considered to be a risk factor for graft rejection Since only 173 recipients were reported to have anti-hla antibodies, we analyzed the impact of High-TBI, Low-TBI, and No-TBI without grouping according to the conditioning intensity (Figure 3). Multivariate analysis suggested that the use of TBI was significantly associated with increased neutrophil engraftment [HR of High-TBI: 24 (95%CI: 12-49), P 5.02; HR of This is the first study to comprehensively assess the impact of TBI on neutrophil engraftment in unrelated HCT from MUD, MMUD, and CBT using a large cohort. The results revealed that TBI-regimens were significantly associated with neutrophil engraftment in both the MAC and RIC groups of the CBT cohort. Particularly, TBI provided a benefit when recipients received HLA-mismatched CBT or had anti-hla antibodies. Additionally, in cases of CBT with a low number of CD34- positive cells, TBI may improve the probability of engraftment only in the MAC setting. Conversely, TBI did not have any favorable impact on engraftment for unrelated BMT in the current practice for standardrisk leukemia. As small studies have suggested that the risk of graft rejection might be increased in HCT from alternative donors or with the use of RIC regimens, 1,7 10 TBI has been considered to promote donor cell engraftment by suppressing recipient T cells. 1,6,19 However, the recent progress in various types of supportive care may override the concerns in HCT from alternative donors or with the use of RIC regimens. Furthermore, the clinical significance of TBI or the conditioning intensity may differ among recent HCT strategies. Thus, this study was planned to provide insight into whether the conditioning intensity or irradiation is most important for successful engraftment in HCT from alternative donors. In unrelated BMT cohorts, even if an HLA-mismatched donor was selected, neither the conditioning intensity nor TBI had a favorable impact on prompt neutrophil engraftment (Figure 1B and Supporting Information Table S3). This tendency was also observed when antigenbased HLA-mismatched HCT was analyzed instead of allele-based HLA-mismatched cohorts (data not shown). Unexpectedly, multivariate analyses showed that High-TBI-MAC was associated with delayed neutrophil engraftment in the MUD cohort (Figure 1B and Supporting Information Table S3), although the actual engraftment probabilities were fairly similar in a univariate analysis (Figure 1A). While the reason for this result is still unclear, damage to the marrow environment due to High-TBI-MAC may eventually result in impaired engraftment, as recently reported. 20 In summary, the addition of TBI as well as an increased conditioning intensity might be unnecessary to achieve neutrophil engraftment in the recent practice of unrelated BMT. Conversely, in the CBT cohort, TBI still seems to be necessary for prompt neutrophil engraftment and may be more critical than the
7 177 conditioning intensity (Figures 1A,B and Supporting Information Table S3). In general, graft failure in CBT is associated with HLA-disparity, 16,17,21 a lower dose of infused TNC or CD34-positive cells, 16 and the presence of anti-hla antibodies, although these issues are still amatterofdebate. 16,17 The current large-size cohort enabled us to further analyze the impact of TBI among the subgroups with these risk factors for graft rejection in the CBT cohort. This study uniquely demonstrated that the addition of TBI to conditioning could provide an advantage for increased neutrophil engraftment in CBT with HLAdisparity and anti-hla antibodies. In the case of an immune interaction between the donor and recipient, TBI might have immunosuppressive potential and prevent graft rejection. Conversely, with a lower infused cell dose, the favorable effect seen with the use of TBI might be limited in the specific MAC setting. Further advances will be required to overcome the disadvantage of a lower infused cell dose in CBT. Recently, novel no-tbi regimens like Flu-Bu-Mel have been investigated and seem to be promising for achieving sufficient neutrophil engraftment in CBT recipients with high-risk leukemia. 22 Although the number of patients in the current cohort who received Flu-Bu-Mel was too small to analyze, it might replace TBI in CBT in the future. If we focused on CBT patients who received mycophenolate mofetil (MMF) as GVHD prophylaxis, no significant difference in engraftment was observed among the five conditioning types, although the population was small (data not shown). It could be another promising strategy to include MMF if the addition of TBI was not suitable. This study has several limitations due to its retrospective nature. The selection of the conditioning regimens and the use of TBI are usually based on several clinical factors, including age, disease, and disease risk. Therefore, there might be some selection preference or bias due to the various patient backgrounds. As most CBT used single cord blood in this cohort, other registry studies are necessary to address whether the impact of TBI differ between single and double CBT. However, the use of a large cohort revealed that TBI had different impacts on neutrophil engraftment according to the donor types, and made it possible to identify which recipients may benefit from the use of TBI in CBT. In conclusion, TBI-regimens had no impact on neutrophil engraftment in the current practice of unrelated BMT from MUD or MMUD. However, TBI is still necessary to enhance engraftment in CBT, regardless of the conditioning intensity. Especially, recipients who receive CBT with two or more HLA-allele mismatches or with anti-hla antibodies may benefit from the addition of TBI to the conditioning regimen. Further observational analyses from other large registry databases would be warranted before we can reach definitive conclusions regarding the use of TBI. In addition, even if we used TBI, the probability of neutrophil engraftment was lower in CBT compared with the other BMT. Therefore, further investigation to enhance overall engraftment achievement in CBT is still equired. ACKNOWLEDGMENTS The authors are grateful for the work of all of the physicians and data managers at the centers that contributed valuable data on transplantation to the Japan Society for Hematopoietic Cell Transplantation (JSHCT), the Japan Marrow Donor Program (JMDP), and the Japan Cord Blood Bank Network (JCBBN). They would also like to thank all of the members of the Transplant Registry Unified Management committees at JSHCT, JMDP, and JCBBN for their dedicated data management. This work was supported in part by a Research Grant for Allergic Disease and Immunology from the Japanese Ministry of Health, Labor, and Welfare (Y.A.). H.N. was a recipient of research awards from Jichi Medical University. AUTHOR CONTRIBUTIONS H.N. designed the study, analyzed data, and wrote the manuscript. S.F., K.Y., M.Onizuka., and A.S. advised on methods and wrote the manuscript. K.O., K.M., and N.U. collected data and revised the manuscript. M.T., T.I. and T.F. collected data, revised the manuscript, and were responsible for data management at JMDP, JCBBN, and JSHCT. Y.A. managed the unified registry database and revised the manuscript. M.Ogata. advised on the methods, wrote the manuscript, and was responsible for the Complication-WG of the JSHCT. REFERENCES [1] Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124: [2] Nakasone H, Fukuda T, Kanda J, et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50: [3] Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999;17: [4] Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95: [5] Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997; 90: [6] Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76: [7] Topolsky D, Crilley P, Styler MJ, Bulova S, Brodsky I, Marks DI. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. Bone Marrow Transplant. 1996;17: [8] Mehta J, Powles RL, Mitchell P, Rege K, De Lord C, Treleaven J. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning. Bone Marrow Transplant. 1994;13: [9] Schultz KR, Ratanatharathorn V, Abella E, et al. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. Bone Marrow Transplant. 1994;13:
8 178 [10] Shaw BE, Russell NH, Devereux S, et al. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica. 2005;90: [11] Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15: [12] Marks DI, Wang T, Perez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosomenegative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116: [13] Luger SM, Ringden O, Zhang MJ, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012;47: [14] Atsuta Y, Suzuki R, Yoshimi A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86: [15] Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transplant. 2013;48: [16] Ruggeri A. Alternative donors: cord blood for adults. Semin Hematol. 2016;53: [17] Ruggeri A, Paviglianiti A, Gluckman E, Rocha V. Impact of HLA in cord blood transplantation outcomes. HLA. 2016;87: [18] Takanashi M, Atsuta Y, Fujiwara K, et al. The impact of anti-hla antibodies on unrelated cord blood transplantations. Blood. 2010; 116: [19] Adkins DR, DiPersio JF. Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol. 2008;15: [20] Wilke C, Holtan SG, Sharkey L, et al. Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen. Radiother Oncol. 2016;118: [21] Stevens CE, Carrier C, Carpenter C, Sung D, Scaradavou A. HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. Blood. 2011; 118: [22] Yamamoto H, Uchida N, Yuasa M, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2016;22: SUPPORTING INFORMATION Additional Supporting Information may be found in the online version of this article.
ASBMT. Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation
Biol Blood Marrow Transplant 19 (2013) 247e254 Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation ASBMT American Society for Blood and Marrow
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationGraft-versus-host disease-free relapse-free survival, which is defined
ARTICLE Stem Cell Trasplantation EUROPEAN HEMATOLOGY ASSOCIATION Haematologica 2016 Volume 101(11):1592 Ferrata Storti Foundation Comparison of graft-versus-host disease-free, relapse-free survival according
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationRESEARCH ARTICLE. Introduction Wiley Periodicals, Inc.
Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older AJH Takaaki Konuma, 1 * Nobuhiro Tsukada, 2 Junya
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationNiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More information2/4/14. Disclosure. Learning Objective
Utilizing Intravenous Busulfan Pharmacokinetics for Dosing Busulfan And Fludarabine Conditioning Regimens In Institutions Where The Capability Of Doing Pharmacokinetics Is Not Present Shaily Arora, PharmD
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationAbstract ORIGINAL RESEARCH ARTICLE
Received: 17 October 2018 Accepted: 23 October 2018 DOI: 10.1002/hon.2566 ORIGINAL RESEARCH ARTICLE Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationSamples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationUMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationEffect of HLA mismatch on acute graft-versus-host disease
Int J Hematol (2013) 98:300 308 DOI 10.1007/s12185-013-1405-x PROGRESS IN HEMATOLOGY New clinical and basic aspects of graft-versus-host disease Effect of HLA mismatch on acute graft-versus-host disease
More informationClinical Use of Umbilical Cord Blood Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationOne-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationHematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden
More informationRelated haploidentical donors versus matched unrelated donors
Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (213) 486e491 Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies
More informationEffect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Authors: Hirohisa Nakamae, 1 Katharine A. Kirby, 1 Brenda M. Sandmaier, 1,2
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationAlloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche
Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Massimo Fabrizio Martelli Ematologia ed Immunologia Clinica Università degli Studi di Perugia 41 Congresso Nazionale
More informationEffect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, 1,2 John E. Wagner, 1,3 Todd E. DeFor, 1 Daniel J. Weisdorf, 1,2 Claudio
More informationSalvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts
Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka Gyurkocza, Thai M. Cao, 2 Rainer F. Storb, Thoralf
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationPublished Ahead of Print on September 20, 2013, as doi: /haematol Copyright 2013 Ferrata Storti Foundation.
Published Ahead of Print on September 20, 2013, as doi:10.3324/haematol.2013.094193. Copyright 2013 Ferrata Storti Foundation. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia
More informationClinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes
Advances in Hematology Volume 2011, Article ID 601953, 8 pages doi:10.1155/2011/601953 Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Jason R. Westin, 1 Rima M. Saliba, 1 Marcos
More informationRIC in Allogeneic Stem Cell Transplantation
RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationSECOND ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD SYMPOSIUM
Biology of Blood and Marrow Transplantation 10:728-739 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1010-0009$30.00/0 doi:10.1016/j.bbmt.2004.06.010 SECOND ANNUAL INTERNATIONAL
More informationBMT CLINICAL TRIALS NETWORK RIC vs. MAC Protocol # 0901 Version 5.0 dated March 3, 2014
Core Study Participants: Baylor College of Medicine (Methodist ) BMT at Northside Hospital Case Western Reserve University Consortia Cleveland Clinic Foundation Oregon Health and Science University University
More informationAllogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( )
TRANSPLANTATION Allogeneic hematopoietic stem cell transplantation from family members other than -identical siblings over the last decade (1991-2000) Yoshinobu Kanda, Shigeru Chiba, Hisamaru Hirai, Hisashi
More informationCord-Blood Transplantation in Patients with Minimal Residual Disease
The new england journal of medicine Original Article Cord-Blood Transplantation in Patients with Minimal Residual Disease Filippo Milano, M.D., Ph.D., Ted Gooley, Ph.D., Brent Wood, M.D., Ann Woolfrey,
More informationSummary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
More informationBusulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate
Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationHematopoietic Cell Transplantation in Bone Marrow Failure Syndromes
Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes The The 44 th th WBMT WBMT SYMPOSIUM 2017 2017 Riyadh, Saudi Saudi Arabia Arabia Mouhab Mouhab Ayas, Ayas, MD MD Department of Pediatric
More informationKEY WORDS: Total body irradiation, acute myelogenous leukemia, relapse
The Addition of 400 cgy Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality
More informationMedical Policy. MP Placental and Umbilical Cord Blood as a Source of Stem Cells
Medical Policy MP 7.01.50 BCBSA Ref. Policy: 7.01.50 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Surgery Related Policies 8.01.20 Hematopoietic Cell Transplantation for Non- Hodgkin Lymphomas
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationHaploidentical Donor Transplants: Outcomes and Comparison to Other. Paul V. O Donnell BSBMT Education Day London 12 October 2011
Haploidentical Donor Transplants: Outcomes and Comparison to Other Donor Types Paul V. O Donnell BSBMT Education Day London 12 October 2011 Clinical Problem: Identification of a Donor for Allogeneic Transplantation
More informationOptimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS)
Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) H. Joachim Deeg Myelodysplastic syndrome (MDS) is a hemopoietic stem cell disorder that is potentially curable by transplantation
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationDoes anti-thymocyte globulin have a place in busulfan/fludarabine
ORIGINAL ARTICLE Korean J Intern Med 2016;31:750-761 Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Young
More informationProphylactic and therapeutic treatment of graft versus host disease in Japan
Int J Hematol (2015) 101:467 486 DOI 10.1007/s12185-015-1784-2 PROGRESS IN HEMATOLOGY The latest development in GVHD management Prophylactic and therapeutic treatment of graft versus host disease in Japan
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationComparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:1326-1334 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1212-0001$32.00/0 doi:10.1016/j.bbmt.2006.08.035 Comparison of Reduced-Intensity
More informationHigh dose cyclophosphamide in HLAhaploidentical
High dose cyclophosphamide in HLAhaploidentical stem cell transplantation Ephraim J. Fuchs, M.D., M.B.A. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins fuchsep@jhmi.edu Alternative Donor Transplantation:
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationPost Transplant Management for Sickle Cell. Title
Post Transplant Management for Sickle Cell Title Kimberly Kasow, DO October 14, 2016 Thank you for this opportunity to present this information I have no financial interests to disclose. Goal of Transplant
More informationRevista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento).
Depletion of TCR alpha/beta+ T-lymphocytes from grafts for haplo haematopoietic CELL transplantation (HCT) in children Heilmann C, Ifversen M, Haastrup E, Fischer-Nielsen A. Haematopoietic Cell Transplantation
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationAllogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission Je-Hwan Lee 1, Sung-Soo
More informationNeed considerable resources material and human.
TRAN VAN BINH INTRODUCTION Hematopoietic Stem cell transplantation: the best way to manage Malignancies and non Malignant blood disorders. Need considerable resources material and human. In developping
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationHee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je
More informationKT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey.
(2001) 28, 1031 1036 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Acute myeloid leukaemia Partially mismatched related donor bone marrow transplantation as salvage
More information